Anda di halaman 1dari 3


GlaxoSmithKline Pharmaceuticals Ltd (GSK India) has its roots dating back to when it
established in the year 1924. GSK is one of the oldest and leading research-based
healthcare and pharmaceutical company. The company's product assortment includes
prescription medicines and vaccines. The prescription medicines range across therapeutic
areas such as anti-infectives, dermatology, gynaecology, diabetes, cardiovascular disease
and respiratory diseases. The company is the market leader in most of the therapeutic
categories in which it operates and has six products in the top 50 brands. GSK also offers
a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused
by H, influenzae, chickenpox, diphtheria, pertussis, tetanus and others. Vaccines division
is ranked first in a fast-growing vaccines market.

GSK has two manufacturing units in India, located at Nashik and Thane as well as a
clinical development centre in Bangalore. The state of art plant at Nashik makes
formulations while bulk drugs are manufactured at Thane. During the year 1956, the
primary production of vaccines begins at Worli. In 1960's the Infant foods manufactured
at milk drying plant at Aligarh was came to existence and also manufacturing facility for
pharmaceuticals opened in Mumbai. After a year in 1961,Vitamin A and betamethasone
manufactured at new plant at Thane using imported raw materials. The company
registered as a limited company in the year 1968 and the Animal health products were
introduced in the same year. The Research & development laboratory was built at Thane
in the year 1971 and the company relocated the SmithKline & French plant from Mumbai
to Bangalore. The Nashik factory was commissioned during the period of 1983.
SmithKline & Beecham becomes a public limited company under the new name of
Eskayef Limited in the year 1984 and one new Plant was sets up in Mysore for
manufacture of bulk drugs. In 1985, the company's second basic drugs factory was
inaugurated at Ankleshwar, Gujarat.

Joint venture projects Vegepro Foods and Feeds Limited and K G Gluco Biols were
launched in the year 1986. The company's name was changed to Glindia Limited in 1987.
Production of bulk drug Ranitidine was commenced at Ankleshwar in the year 1988 and
in the same year a joint venture project with Hindustan Foods Limited was made for the
manufacture of extruded foods at Usgao, Goa. During the period of 1989, commenced its
Zinetac production at Nashik and again the company's name were changed from Glindia
Limited to Glaxo India Limited. The production of the bulk drug, cephalexin was
commenced at Ankleshwar and the salbutamol inhalers at Nashik in the year 1990. Glaxo
rated amongst the first five of India's most respected companies (4th place), in a survey
by Businessworld magazine. An agreement was signed with the Council of Scientific and
Industrial Research (CSIR) during 1991. In the year 1992, the company sold its trade
investments in Vegepro and Feeds Limited, subsequently in the next year (1993) sold its
investment in Hindustan Foods Limited and Dempo Dairy Industries Limited. Cetzine, a
second-generation anti-histamine and research product of UCB Pharma (Belgium) was
launched under a co-marketing agreement. In the same year Glaxo received recognition
from the Ministry of Commerce as an export house. The company sold its Family
Products Division in the year 1994 to H J Heinz for a sum of Rs 210 crores. The Mysore
plant received ISO 9002 certification and the new Iodex plant was inaugurated in
Bangalore. Government approved state-of-the-art Pharmacy Research & Development
Centre (PR&D) inaugurated at Thane in the year 1995 to cater to the unmet medical
needs and to exploit local commercial opportunities.

Glaxo acquired Biddle Sawyer Group of Companies in the year 1998, which was
struggled in the year before. Gramin Arogya Vikas Sanstha - a rural development
programme initiated in Nashik. During 1999, Glaxo India completed it 75 years of
operations in India. During the year 2000, Agrivet Farm Care (AFC) tied up with Merial,
the world's largest Animal Health Company, to market poultry vaccines. The company
ranked 6th in 'Business Today' - Stern Stewart & Co. listing of India's best Wealth
Creator Companies and also the launched Seretide for Asthma. The Merger of
SmithKline Beecham Pharmaceuticals (India) Limited into Glaxo India Limited was
completed and the name of the company was changed to the present name
GlaxoSmithKline Pharmaceuticals Limited in India. Businessworld and the Indian
Market Research Bureau (IMRB) named GlaxoSmithKline as India's most respected
Pharmaceutical Company in a survey in the year 2003 and launched Cetzine (Cetirizine;
anti-histamine), Zimig (terbinafine; anti-infective), CCM (calcium citrate maleate;
nutritional), Cobadex CZS (multivitamin with trace elements).

In the year 2004, the company launched Priorix (measles, mumps, rubella vaccine) and
the 'Augmentin' becomes the No. 1 pharmaceutical brand, as rated by IMS. The
foundation stone laid for GSK vaccines plant at Nashik in the year 2005. Launched oral
contraceptives: Elogen (desogestrel and ethinylestradiol) and Zerogen (progesterone only
pill) and has the company entered into the diabetes therapeutic segment with the launch
of Windia (rosiglitazone) and Windamet (rosiglitazone and metformin). During the
period of 2006, the company's Augmentin grows to a Rs. 100 crore brand. In-licensing
alliance was made with Eisai Pharmaceuticals, Japan and launched Parit (rabeprazole;
gastrointestinal therapy area). GlaxoSmithKline divests its Agrivet Farm Care (AFC)
animal health business in the year. In 2007, the company launched Carzec (carvedilol)
and Zemetril (cefprozil). The Company has opened its new Medicinal Chemistry
Laboratory at its research and development facility in Singapore's biomedical research
hub, Biopolis in March of the year 2007. After the exit from animal health business, GSK
Pharma has divested its other peripheral business of fine chemicals as well in the same
year 2007 with consideration of Rs.240 crores on slump sale basis to Thermo Electron
LLS India Private Ltd. The company launched two of its new innovative Diphtheria,
Tetanus and acellular Pertussis (DTP) vaccines, such as Boostrix and Infanrix in January
of the year 2008. Also the company in well positioned to launch the breast cancer drug,
Tykerb and the rotavirus vaccine, Rotarix during the year 2008.

GlaxoSmithKline Pharmaceuticals Limited, a subsidiary of GlaxoSmithKline plc is

consecutively moving with mission to improve the quality of life by enabling people to
do more, feel better and live longer. This mission drives the company to make a real
difference to the lives of millions of people with commitment to effective healthcare
solutions. With opportunities in India opening up, GSK India is aligning itself with the
parent company in areas such as clinical trials, clinical data management, global pack
management, sourcing raw material and support for business processes including